secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107390
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development
--------------------------------------------------------------------------------

- Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.
- Cash, equivalents & restricted cash $39.8M; plus $36.3M in NIH grant funds; runway into Q2 2027.
- Closed $30M registered direct offering of 14.7M shares to institutional investors.
- FDA aligned on registrational path for zervimesine (CT1812) in Alzheimer's disease.
- Phase 2 START study >75% enrolled; expanded access program for dementia with Lewy bodies ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/0001104659-25-107390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/tm2530237d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer